Hutchmed (china) Share Discussion Threads

[shaker44] 13/3/2019 04:05

Sportii, I checked with my oncologist in Thailand and she confirms they do/will use drugs approved in china, even though not approved by usa fed. I believe that is true through southeast Asia incl India.

[sportii] 13/3/2019 03:54

dbadvn, Thank you for your efforts.
I wish to know if the company has any plans of expanding its commercial platform into the neighboring countries and subsequently a Global pharma. That would allow Elunate (and in future, other drugs in the pipeline) to be marketed outside China.

[lauders] 13/3/2019 02:02

DBADVN - Thanks for the offer re: questions. I would be interested in knowing why HCM don't look to market more drugs within China from other global pharmaceutical companies (i.e. AstraZeneca’s Seroquel (quetiapine) and Merck Serono’s Concor (bisoprolol)) like they have done in the past via their commercial business? Given their footprint in China and number of reps this seems like a "no-brainer" to generate more income to fund the research side even more. This is from page 38 of the Feb 2019 Trinity Delta note:

These businesses showed strong organic growth, with investment in increasing sales forces (from c 1,000 reps in 2008 to c 2,400 now) and geographic expansion into other adjoining regions paying dividends.

I suppose it isn't as simple as that and there are numerous reasons why they haven't done deals on more products like those just mentioned. Would be good to know more about this point. Cheers.

[thornyone] 12/3/2019 17:29

Your analysis seems more optimistic than the following:

(Sharecast News) - Hutchison China Meditech on Monday reported a drop in sales and increased annual loss after the implementation of new government policy in China.
The pharmaceutical company, which is also know as Chi-Med, reported a loss before tax of $86.7m for the year ended 31 December, an increase of 62% compared to the year before, after revenues dropped by 20% to $156.2m.

The AIM traded company said the decrease in revenue was due to a new two-invoice system in China, a new government policy intended to restrict the number of layers in the drug distribution system in China and to improve transparency, compliant business conduct, and efficiency and thereby lower the cost of drugs

Chi-Med said this has led to a shift in the company's revenue recognition for some third-party drugs, with the sales model for Seroquel, in which consolidated revenues historically reflected total gross sales of Seroquel, shifted to a fee-for-service model.

Losses were also exacerbated by an increase in research & development expenses on an adjusted basis to $142.2m from $88.0m the year before, as development of the company's eight clinical drug candidates picks up pace.

Simon To, chairman of Chi-Med, said: "We took a big step in 2018 to expand our US development capability in order that we can take full advantage of the global potential of our assets. We also entered the immuno oncology arena through multiple development collaborations combining PD-1 antibodies with our highly selective small molecules. The increased investment in all these activities is partially offset by robust income from our commercial operation in China, which also serves as a very powerful platform for future product launches."

[dbadvn] 12/3/2019 16:28

Meeting the CFO tomorrow am .

Any questions anyone wants me to put to him?

[nerdofsteel] 11/3/2019 13:54

A good extract to post Lauders! ADR's down slightly but at this point very low volume as usual. I was particularly encouraged by the overall revenue numbers which were much higher than forecast.

[mad foetus] 11/3/2019 13:31

have bought ack in, GLA

[nerdofsteel] 11/3/2019 07:40

I am midway through reading today's Results announcement but my initial thoughts are that these are materially ahead of expectations on many fronts. It's also great to see some initial Fruquintinib CRC sales numbers which appear to have started really well indeed.

[nerdofsteel] 08/3/2019 12:01

Monday

2018 Full Year Results
Announcement released: 7am BST (3pm HKT / 3am EDT)

Presentation webcast & call: 9am BST (5pm HKT / 5am EDT)
>> Click here for the webcast
US conference call: 9am EDT (1pm BST/9pm HKT)
---
To participate by phone, please use one of the following numbers. The conference ID for the calls is "Chi-Med".

UK Toll Free 0808 109 0700
USA Toll Free 1 866 966 5335

China Toll Free 4001 200558
Hong Kong Toll Free 800 900 476
Italy Toll Free 800 986 477
Singapore Toll Free 800 120 4789
Switzerland Toll Free 0800 800 038

New York City Local Access [phone]
London/Other International [phone]

[dbadvn] 05/3/2019 15:01

Never wrong to take a profit.

[nerdofsteel] 05/3/2019 08:20

I probably bought some of yours mad! I only buy since 2014 but wish I'd kept my 20,000 holding that I bought years ago for around £2.50 each!

[lauders] 05/3/2019 01:32

VERY short term MF! However, appreciate the honesty. You did make a profit too so that is good. I am not one for timing the markets and prefer to just buy and hold. You have made a profit whereas I am showing a loss at the moment. So, so far you are the winner ;-) Look forward to welcoming you back!

[mad foetus] 04/3/2019 19:23

Time to fess up! I sold this pm for a small profit. Saw the way Wall Street was going and closed a lot of positions. Hopefully back soon, was fully expecting a big up day for HCM in US.

[nerdofsteel] 04/3/2019 16:36

All good! glad to see you back mad foetus and also your post Lauders.

FY18 results next Monday - always a good event, particularly looking fotr FY19 guidance and it would be nice to get some kind of comments on Elunate sales even though it may be a bit early for anything formal.

[mad foetus] 04/3/2019 13:59

According to stocktwits Deutsche have initiated coverage with a buy reco. I know no more

[mad foetus] 04/3/2019 11:25

The US always drives the share price here and the thaw in Chinese relations may help us along imo. But you cannot ignore the long term record of creating shareholder value here

[lauders] 04/3/2019 11:17

Looks like good timing mad foetus. Perhaps a few were waiting for a break through the 4000p barrier. I should have bought more in the mid-3000p area but alas no funds of a sufficient size to make a buy worthwhile. Will be good to at least see how the sales of Elunate have started. If there are good signs there then that would be a good sign for HCM.

[mad foetus] 04/3/2019 10:18

Back in this morning, GLA

[nerdofsteel] 03/3/2019 17:30

I've put together my favourite collection of Warren Buffet quotes. I do think they are appropriate to an investment in Ch-Med in so many ways:

"If you aren’t willing to own a stock for ten years, don’t even think about owning it for ten minutes”
“Price is what you pay; Value is what you get.”
“Risk comes from not knowing what you are doing.”
“It’s far better to buy a wonderful company at a fair price, than a fair company at a wonderful price.”
“Only buy something that you’d be perfectly happy to hold if the market shut down for 10 years.”
“The stock market is designed to transfer money from the active to the patient.”
“Wide diversification is only required when investors do not understand what they are doing.”

[nerdofsteel] 03/3/2019 13:22

Only a week until 2018 Results!

[nerdofsteel] 23/2/2019 15:20

Despite recent setbacks, I think this article is also a useful reminder about the potential here, especially with regards to the biggest prize, which is Savolitinib in NSCLC

[nerdofsteel] 23/2/2019 15:20

Despite recent setbacks amones, I think this article is also a useful reminder about the potential here, especially with regards to the biggest prize, which is Savolitinib in NSCLC

[nerdofsteel] 20/2/2019 10:36

Trinity Delta Update 20th February

hxxps://docs.wixstatic.com/ugd/07354c_ceb68a957be94a39a937b752216bddf4.pdf

For anyone interested, you can sign up to TD's Healthcare research alerts on their website.

[nerdofsteel] 17/2/2019 08:30

Lots happening as ASCO yesterday

ASCO Genitourinary Cancers SymposiuToday 08:29hxxps://stocksnewsfeed.com/benzinga/chi-med-highlights-preliminary-phase-ii-savolitinib-imfinzi-combination-data-in-advanced-papillary-renal-cell-carcinoma-at-2019-asco-genitourinary-cancers-symposium/?utm_source=dlvr.it&utm_medium=twitter